Steven Cohen Immuno Gen, Inc. Call Options Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $810,000 - $1.49 Million	-450,000 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$2.41 - $5.91 $1.93 Million - $4.73 Million	-800,000 Reduced 64.0%	450,000 $1.22 Million
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $1.97 Million - $4.85 Million	500,000 Added 66.67%	1,250,000 $6 Million
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $6.45 Million - $8.45 Million	750,000 New	750,000 $7.1 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.